Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Disc Dynamics spinal nucleus replacement

This article was originally published in The Gray Sheet

Executive Summary

Firm announces Aug. 2 approval to commence a clinical study of its Dascor disc arthroplasty system. Dascor is a minimally invasive nucleus replacement device intended for patients with disc degeneration not yet severe enough to warrant total disc replacement. Data from the trial, scheduled to begin during the third quarter, will support a premarket approval application for the device. The firm received a CE mark for Dascor in July 2005. Disc Dynamics is vying with NuVasive (NeoDisc), Cryolife (BioDisc) and Raymedica (PDN-Solo) to market the first spinal nucleus replacement system in the U.S. (1"The Gray Sheet" Sept. 5, 2005, p. 5)...

You may also be interested in...



Financing In Brief

Disc Dynamics: Minnesota firm announces completion of $27 million financing round, with funds to go toward development of the minimally invasive Dascor disc arthroplasty system for treating lower back pain associated with degenerative disc disease. The nucleus replacement implant, CE-marked in Europe, is in a prospective, multicenter pilot clinical study in the United States. Privately owned Disc Dynamics was incorporated in 2000, with its first major financing round in 2004 (1"The Gray Sheet" Aug. 7, 2006, In Brief)...

FDA’s Ortho Panel To Consider Study Designs For Less Invasive Spinal Devices

Clinical trial design issues for non-fusion spinal stabilization implants are among topics likely to be discussed by FDA's Orthopedic and Rehabilitation Devices Panel Sept. 9 in Gaithersburg, Md

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.
UsernamePublicRestriction

Register

MT023843

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel